Blog

Today, voters will help determine who oversees the most significant changes in federal cannabis policy in more than 50 years. This blog examines the political and regulatory landscape the next Congress will inherit, including the opportunities and challenges these historic reforms present for medical cannabis patients.

Tomorrow, Wednesday, November 4, at 8 PM ET, join Americans for Safe Access for Midterms Mid-Rescheduling: What's Next for Medical Cannabis?, a special post-election debrief examining how the election results could shape federal cannabis reform, expand patient rights and access to care, or create new obstacles for patients. We'll also discuss what Congress and state governments must do to ensure that federal progress translates into meaningful patient protections.

Nearly 30 years after California voters passed Proposition 215, the nation's first statewide medical cannabis law, the federal government is formally recognizing the medical cannabis programs and dispensaries that patients fought to establish. The April 28, 2026, Attorney General's order moved qualifying state-licensed medical cannabis into Schedule III of the Controlled Substances Act (CSA), recognizing cannabis' accepted medical uses. On October 30, the Department of Justice announced that the DEA was moving forward with federal registrations for more than 900 medical cannabis dispensaries across the first seven states.

These developments represent extraordinary progress, but the transition is already exposing challenges that could leave patients without reliable access to their medicine. Federal registration requirements, state licensing structures, product availability, and access to full-spectrum cannabinoid products are among the urgent issues that will require strong patient advocacy. Whether federal recognition becomes a lasting improvement in patients' lives will depend on decisions made by Congress, federal agencies, and state governments in the months ahead.

Federal Recognition Is Not the Same as Patient Access

For decades, patients have fought for the right to use cannabis as medicine. They helped establish state medical cannabis programs, developed relationships with healthcare professionals, and supported businesses that provided products specifically for therapeutic use. Yet even in states where medical cannabis has been legal for years, patients continue to face barriers involving cost, product availability, housing, employment, healthcare, and discrimination.

Many patients still encounter obstacles when discussing cannabis with healthcare professionals, using it in healthcare facilities, or obtaining insurance coverage for their medicine. Others face restrictions that force them to choose between maintaining their treatment and keeping their jobs, housing, or access to federally supported services.

The Attorney General's order creates an important federal legal pathway for qualifying state medical cannabis programs, but it cannot resolve all the issues affecting patient access. The order primarily relies on existing state licensing systems and DEA oversight. It does not establish a comprehensive national medical cannabis program or require healthcare systems to recognize and accommodate patients using cannabis medicines.

The October 30 federal registration announcement demonstrated that the federal government is beginning to implement the new framework. However, it also revealed how much work remains to ensure that patients across the country can benefit, particularly in states where medical cannabis programs have been merged with adult-use markets and in states without comprehensive medical cannabis access programs.

Patients in States with Adult-Use Programs Face Continued Uncertainty

For years, patients in states that legalized adult-use cannabis have watched medical cannabis programs lose resources, dispensaries close or convert to adult-use sales, and products they depended on disappear from shelves. Some states merged medical and adult-use licensing systems, while others allowed businesses to serve both markets through shared facilities and supply chains.

For patients, the consequences have been significant. Products developed to meet specific therapeutic needs, including high-CBD formulations, balanced cannabinoid ratios, and lower-potency preparations, have become less available in some markets as retailers prioritize products for adult use. Many patients now depend on adult-use dispensaries or the largely unregulated hemp-derived cannabinoid market because medical-specific products and services are no longer available in their communities.

These state licensing decisions are now creating challenges under federal law. On October 30, Marijuana Moment reported that DEA had moved to deny federal registration to a Minnesota dispensary because its state license permitted both medical and adult-use cannabis sales. DEA argued that the combined licensing structure did not provide the separation required under federal law and raised additional concerns about Minnesota's medical certification requirements and certain cannabinoid products permitted under state law.

These challenges were anticipated when the Attorney General's order was issued in April. The order established that federal recognition applies to qualifying medical cannabis activities, not adult-use cannabis, and that businesses must comply with federal registration and controlled-substance requirements. However, it provided only 60 days for businesses to submit applications under the expedited registration process, leaving states little time to evaluate and modify licensing systems developed over many years.

After more than a decade of limited federal enforcement against state-regulated cannabis businesses, some states and operators adopted a wait-and-see approach to determining how DEA would implement the order. The October 30 developments now demonstrate that DEA is moving forward with the requirements established in April and provide greater clarity about how those requirements will be applied.

The Minnesota dispute does not invalidate the state's medical cannabis program, but it raises concerns for businesses that applied for DEA registration under similar licensing systems elsewhere. Patients may continue to have access under state law, but businesses operating outside the federal framework remain vulnerable to federal enforcement. If federal authorities begin actively enforcing registration requirements against state-licensed businesses without federal authorization, closures or disruptions could follow, particularly in communities where patients depend on dispensaries operating under dual-purpose licenses.

Similarly, the DEA guidance released October 30 did not introduce a new requirement for federally compliant medical cannabis supply chains. Those obligations were already established under the Attorney General's order. The guidance clarifies how DEA expects registered businesses and qualifying applicants with pending registrations to conduct transactions and establishes November 29 as the date by which timely applicants are expected to verify their trading partners and make necessary supply-chain adjustments.

These requirements could create significant challenges for federally registered dispensaries if cultivators, manufacturers, and distributors cannot qualify for registration or if states have not maintained distinct medical cannabis supply chains. Federal registration offers little practical benefit to patients if their dispensaries cannot obtain the products they depend on, and compliance problems throughout the supply chain could threaten continuity of care.

Anticipating these challenges, ASA issued emergency guidance to state governments in June 2026, urging states to evaluate their medical cannabis programs before the June 26 DEA registration deadline. The guidance called on states with combined medical and adult-use programs to establish clearly defined medical cannabis licensing and supply-chain structures, verify medical-only activity, and help existing businesses prepare for federal registration.

ASA recognized that adapting existing state programs to a new federal framework would require substantial coordination, particularly within such a compressed timeline. With federal registration now underway, state leaders must address these issues urgently and work proactively with DOJ and DEA to determine a path for establishing medical-specific licenses or other compliant structures where necessary. Federal and state officials must also identify practical transition options that protect existing patients and businesses, ensuring that the move toward federal compliance does not disrupt access to medical cannabis.

The Lame-Duck Congress Has Important Work to Finish

Although voters will determine the makeup of the 120th Congress today, the 119th Congress still has critical decisions to make before the end of the year. The FY2027 appropriations process provides an immediate opportunity to protect medical cannabis patients and influence how federal agencies implement the new legal framework.

ASA is urging Congress to preserve the longstanding appropriations protections for state medical cannabis programs, remove proposed language that would interfere with broader rescheduling, and direct federal agencies to update outdated policies that continue to treat medical cannabis patients as categorically engaged in illegal drug use. These include policies affecting federally assisted housing, veterans' healthcare, federal employment, healthcare facilities, disability accommodations, and federally funded services.

Congress must also address the practical challenges emerging from DEA's registration process. Federal agencies need to work with states to establish reasonable pathways for existing medical cannabis businesses, prevent unnecessary disruptions to medical supply chains, and ensure that federal oversight improves rather than restricts patient access.

The pending hemp restrictions create another urgent issue. The 2018 Farm Bill's hemp provisions made CBD and other cannabinoid products available to patients who could not obtain them through medical cannabis programs, but the absence of comprehensive federal safety regulations also allowed an intoxicating hemp market to develop. Congress responded by restricting the definition of hemp, potentially eliminating access to full-spectrum products patients depend on without creating a regulated medical alternative.

Lawmakers should work toward a solution that protects access to appropriate full-spectrum cannabinoid products while establishing enforceable safety standards. Congress can also act now on patient civil rights guidance, improved medical cannabis data collection, healthcare integration, product safety standards, and stronger coordination among federal agencies. These actions cannot replace comprehensive legislation, but they can establish essential protections while longer-term reforms move forward.

States Cannot Wait for Congress to Act

The urgency is particularly great for states with combined medical and adult-use cannabis programs and those with no medical cannabis program at all. Governors, legislators, cannabis regulators, health departments, and attorneys general need to evaluate whether their current medical cannabis licensing systems meet the requirements of the new federal framework and whether patients will have access to federally registered medical cannabis businesses.

For states where medical cannabis businesses operate under dual-purpose licenses, this may require legislative or regulatory changes establishing distinct medical cannabis licenses and clearly defined medical supply chains. States should engage DOJ and DEA directly to clarify federal registration requirements and identify workable transition options before patients experience disruptions.

At the same time, state governments must ensure that patients retain access to medical cannabis products, healthcare professional support, and meaningful patient protections. Rebuilding medical licensing systems cannot become an excuse to reduce the products or services available to patients, nor should complying with federal requirements mean forcing patients to start over in obtaining their medicine.

ASA's state preparedness recommendations provide a roadmap for these discussions, but meaningful progress will require coordination among state officials, federal regulators, medical cannabis businesses, healthcare professionals, and patients. The needs of patients who depend on existing products and dispensaries should help guide the transition, rather than being addressed only after new licensing rules are established.

The 120th Congress Must Build a Medical Cannabis Framework That Works for Patients

The federal government's recognition of state medical cannabis programs demonstrates that existing patient access systems can become part of a lawful national framework. However, the Attorney General's authority has limits. DEA can oversee controlled substances and register businesses, but it is not a healthcare agency equipped to address the full range of patient needs, clinical practices, product development, insurance coverage, and research required for national medical cannabis integration.

ASA's proposed Medical Cannabis & Cannabinoid Act provides a broader approach, including an Office of Medical Cannabis and Cannabinoid Control within the Department of Health and Human Services and a new Schedule VI tailored to cannabis medicines. The proposal would establish a national framework that recognizes whole-plant cannabis and cannabinoid therapeutics, builds on state medical cannabis systems, coordinates federal oversight, strengthens product safety, supports research, and protects patients.

The 2026 elections will shape the political environment in which this work takes place, but the problems facing patients are not waiting for the next Congress to convene. ASA will continue working with policymakers, healthcare professionals, researchers, and patient advocates to ensure that federal recognition becomes the foundation for a comprehensive medical cannabis program rather than another set of regulatory barriers patients must navigate.

Election Day: Make Sure Your Voice Is Heard

Medical cannabis policy has been shaped by nearly 30 years of patient advocacy and civic participation. As the federal government begins recognizing the programs patients fought to establish, understanding where candidates stand on patient rights, medical research, healthcare access, and product safety is an important part of making informed decisions at the ballot box.

Americans for Safe Access has created a comprehensive Voting in the 2026 Elections resource to help voters find their polling locations, verify voting requirements, understand ballot deadlines, and access information about voting options and accommodations. Voters can use these resources to prepare for Election Day and participate in the decisions that will help shape the future of federal and state cannabis policy.

Find Out Where and How to Vote: ASA's 2026 Election Guide

Midterms Mid-Rescheduling: What's Next for Medical Cannabis?

A Post-Election Debrief with Americans for Safe Access

Wednesday, November 4, 2026 | 8:00 PM ET

With a new Congress on the horizon, significant federal policy decisions ahead, and state legislative sessions approaching, what will the election results mean for medical cannabis patients and the future of cannabis policy? Join Americans for Safe Access for a special post-election debrief examining the results and the challenges and opportunities ahead.

We'll discuss what Congress needs to accomplish during the lame-duck session, how states must respond to the new federal registration requirements, what the changing hemp laws mean for patients, and how ASA is preparing for the 120th Congress and state legislative sessions in 2027.

The discussion will also explore how patients, healthcare professionals, advocates, and other stakeholders can work together to ensure that federal progress translates into lasting patient protections, stronger safety standards, and meaningful access to care. As new regulatory decisions unfold, continued participation will be essential to keeping patient needs central to the policies being developed.

RSVP for ASA's November 4 Post-Election Debrief

The past 30 years have demonstrated what patients can accomplish when they organize to change cannabis policy. The next challenge is ensuring that the federal government builds on that progress rather than creating another system that leaves patients behind. ASA will continue working to ensure that medical cannabis reform is measured not simply by changes in federal law, but by improvements in patient safety, protections, and access to care.

Support ASA's ongoing work to protect medical cannabis patients and advance safe access nationwide. Make a donation today.